In a significant development in chronic obstructive pulmonary disease (COPD) management, the Phase IIa COURSE trial, a proof-of-concept study led by AstraZeneca in partnership with Amgen, has revealed key findings about TEZSPIRE (tezepelumab) and its effects on COPD exacerbations. Despite a non-statistically significant overall reduction, a notable subgroup analysis showed potential benefits for patients with […]
Chronic Obstructive Pulmonary Disease, or COPD, is a progressive lung condition that encompasses emphysema and chronic bronchitis, often leading to severe respiratory issues. Affecting approximately 30 million individuals in the United States alone, with half remaining undiagnosed, COPD poses significant health risks including accelerated disease progression and heart complications without proper treatment. This article delves […]
In a significant healthcare development, global pharmaceutical giant Lupin Limited (Lupin) has entered into a groundbreaking collaboration with Mark Cuban Cost Plus Drug Company (Cost Plus Drugs) and the COPD Foundation. This collaboration aims to enhance healthcare access by expanding the availability of Tiotropium Bromide Inhalation Powder, 18 mcg/capsule, for COPD patients in the US. […]
Lupin has announced that its subsidiary in Canada, Lupin Pharma Canada has received approval from Health Canada to market a generic version of Spiriva (tiotropium bromide inhalation powder) for the treatment of chronic obstructive pulmonary disease (COPD) in Canada. Tiotropium Bromide Inhalation Powder is used as a long-term maintenance bronchodilator for patients with COPD, including […]
Lupin through its subsidiary — Lupin Healthcare (UK) has secured approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for Lutio, a generic version of Spiriva (Tiotropium bromide). Lutio has been approved for the treatment of chronic obstructive pulmonary disease (COPD). It is the second inhalation product for the British market from Lupin […]
Zydus Group said that its subsidiary Zydus Pharmaceuticals (USA) has secured final approval from the US Food and Drug Administration (FDA) to market Roflumilast Tablets in 500mcg strength and tentative approval for Roflumilast Tablets in 250mcg. Roflumilast Tablets is the generic version of Dalires. Zydus said that as it is one of the first applicants […]
Lupin Limited said that its subsidiary Lupin Healthcare (UK) has secured approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for Luforbec (beclometasone dipropionate/formoterol fumarate dihydrate) 100/6 µg pressurized metered dose inhaler (pMDI). Vinita Gupta – CEO of Lupin Limited said: “We are truly delighted to receive the first marketing authorization for generic Fostair […]
Glenmark Pharmaceutical has announced the UK launch of Tiogiva, a bioequivalent version of Tiotropium Bromide dry powder inhaler (DPI), for the treatment of chronic obstructive pulmonary disease (COPD). Tiotropium Bromide DPI is a bioequivalent version of Boehringer Ingelheim’s Spiriva Handihaler. As per data from IQVIA, Tiotropium DPI’s market size was $450 million in the European […]
Lupin Limited said that it has launched the authorized generic version of Brovana (arformoterol tartrate) Inhalation Solution 15 mcg /2 mL, unit-dose vials, of Sunovion Pharmaceuticals, in the US. Arformoterol Tartrate Inhalation Solution 15 mcg/2 mL has approval in the US for the long-term, twice-daily maintenance treatment of bronchoconstriction in patients having chronic obstructive pulmonary […]
